-

Frazier Life Sciences Adds Experienced Biopharmaceutical Executive to Team

MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Life Sciences announced the addition of Jan Møller Mikkelsen as a Senior Advisor. He has over 30 years of experience as a biopharmaceutical executive.

Mr. Mikkelsen founded Ascendis Pharma (NASDAQ: ASND) and currently serves as full-time President and Chief Executive Officer, as well as a board member. He previously served as President and Chief Executive Officer of LifeCycle Pharma A/S (acquired by Asahi Kasei Pharma), as well as President of the Pharmaceutical Division of Maxygen, Inc. Prior to that, Mr. Mikkelsen co-founded ProFound Pharma A/S (acquired by Maxygen, Inc.), where he served as Co-Chief Executive Officer. He has also held various positions at Novo Nordisk A/S, including Vice President of Protein Discovery. In addition, Mr. Mikkelsen serves as Chairman of the board of directors for Hummingbird Bioscience.

Mr. Mikkelsen received a Cand. Scient. degree in Biochemistry from the University of Odense, Denmark, and pursued his post-doctoral research at Children’s Hospital in Oakland, CA.

“I have known Jan for many years and am very excited to have him join Frazier,” said Managing Partner Albert Cha. “He is a highly experienced biopharmaceutical executive, and we look forward to working with him to identify and evaluate attractive life sciences investment opportunities.”

About Frazier Life Sciences

Frazier Life Sciences invests globally in private and publicly-traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences funds comprise over $3.3 billion in capital raised, including venture funds focusing on company creation and private companies, and a public fund focused on small and mid-cap public companies. Since 2005, 62 Frazier Life Sciences portfolio companies, many of which were created or seeded by Frazier, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals with deep expertise in biopharmaceuticals, primarily located in Menlo Park, California (headquarters), San Diego, Seattle, Boston, New York, and London.

For more information about Frazier Life Sciences, please visit www.frazierls.com.

Contacts

Frazier Life Sciences
Kate Schykerynec
Phone: 650.325.5156
Email: kate@frazierls.com

Frazier Life Sciences



Contacts

Frazier Life Sciences
Kate Schykerynec
Phone: 650.325.5156
Email: kate@frazierls.com

More News From Frazier Life Sciences

Frazier Healthcare Partners Announces Definitive Agreement to Acquire MatrixCare

SEATTLE--(BUSINESS WIRE)--Frazier Healthcare Partners ("Frazier"), a private equity firm focused exclusively on the healthcare industry, today announced it has entered into a definitive agreement to acquire MatrixCare (the “Company”) from Resmed (NYSE & ASX: RMD).MatrixCare is a leading provider of cloud-based EHR software purpose-built for out-of-hospital care settings, including skilled nursing, senior living, home health, hospice, and life plan communities. A multi-year winner of the Best...

Frazier Healthcare Partners Adds Stephen Krupa as an Executive in Residence

SEATTLE--(BUSINESS WIRE)--Frazier Healthcare Partners, a private equity firm focused exclusively on the healthcare industry, is pleased to announce that Stephen Krupa has joined the firm’s Growth Buyout team as an Executive in Residence. In this role, Mr. Krupa will support Frazier’s investment professionals with diligence efforts and sector insights, while also advising portfolio leadership teams on operational performance, strategic growth initiatives, and financial execution.Mr. Krupa brings...

Frazier Healthcare Partners Adds Milton Boyer as an Executive in Residence

SEATTLE--(BUSINESS WIRE)--Frazier Healthcare Partners, a private equity firm focused exclusively on the healthcare industry, is pleased to announce that Milton Boyer has joined the firm’s Growth Buyout team as an Executive in Residence. Mr. Boyer brings nearly 30 years of leadership experience in pharmaceutical contract development and manufacturing, with a track record of building and scaling businesses through complex carve-outs, integrations, manufacturing expansions, and operational transfo...
Back to Newsroom